We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance to Develop Diagnostic Tests

By Labmedica staff writers
Posted on 01 Sep 2005
An alliance to develop and commercialize novel proteomic diagnostic tests based on proprietary technology has been announced by Ciphergen Biosystems, Inc. More...
(Fremont, CA, USA) and Quest Diagnostics Inc. (Lyndhurst, NJ, USA).

The tests will be based on the surface-enhanced laser desorption ionization (SELDI) ProteinChip technology of Ciphergen. The partnership will focus on selected assays chosen from Ciphergen's pipeline over the next three years. Quest has purchased 6.2 million shares of Ciphergen's common stock for U.S.$15 million, about 17% of the company's outstanding shares, and has a five-year warrant to purchase an additional 2.2 million shares for $3.50 per share. Quest has also agreed to loan Ciphergen up to $10 million to fund certain development activities. This loan would be forgiven, based on the achievement of certain milestones.

"We are very excited about our strategic alliance with Quest Diagnostics to develop novel proteomic tests based on our proprietary biomarkers and ProteinChip system,” said William E. Rich, Ph.D., CEO of Ciphergen Biosystems. "Together, we have the opportunity to translate biomarker discovery into clinical diagnostic tests that will address unmet medical needs and improve patient care.”

Ciphergen's ProteinChip systems enable protein discovery, characterization, identification, and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biologic function at the protein level.




Related Links:
Ciphergen
Quest Diagnostics

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.